February 9, 2024 7:33am

Watch on Netflix: “Bad Surgeon, Love under the Knife” a back story involving Harvard Apparatus RN (HRGN) … < www.hregen.com  > formerly Biostage and Dr. Paolo Macchiarini formerly a world famous for his revolutionary stem cell-infused windpipe transplants. 

“There's just one problem: His patients kept dying.”

Also answers the question of WHY Biostage (BSTG) and its former Chairman, CEO Biostage and current board member David Green of re-named company paid $5 million dollars to the VICTIM’s family and they are trying to re-test the artificial esophageal windpipe yet again at two (2) locations!

Are the remaining investors ready for the upcoming private placement of share increasing outstanding shares!


Will it help a Registration Statement Form S-8 to be filed with the SEC relating to an aggregate of 4,000,000 shares of common stock, $0.01 par value per share of Harvard Apparatus Regenerative Technology, Inc., a Delaware corporation issuable under the Company’s Amended and Restated Equity Incentive Plan, as amended.

Also, their cash “runway” to fund operations is depleted Q4/2023 after a $90.1 million loss over the years in business? In 10-Q, in the event HRGN is unable to raise additional capital from outside sources before or during the first quarter of 2024, it may be forced to curtail or cease its operations. OTCQB: HRGN continues a “going concern”

More to come as: QUESTIONABLE …Unaudited Interim Financial Information

The interim condensed consolidated balance sheet as of September 30, 2023, condensed consolidated interim statements of operations and stockholders’ equity (deficit) for the three and nine months ended September 30, 2023 and 2022, and cash flows for the nine months ended September 30, 2023 and 2022 are unaudited.

The interim unaudited condensed consolidated financial statements have been prepared in accordance with GAAP on the same basis as the annual audited consolidated financial statements and, in the opinion of management, reflect all adjustments necessary for a fair statement of the Company’s financial position as of September 30, 2023, its condensed consolidated results of operations and stockholders’ equity (deficit) for the three and nine months ended September 30, 2023 and 2022, and cash flows for the nine months ended September 30, 2023 and 2022.

 The financial data and other information disclosed in these notes related to the three and nine months ended September 30, 2023 and 2022 are unaudited.

WHY...??

The results for the three and nine months ended September 30, 2023 are not necessarily indicative of results to be expected for the year ending December 31, 2023, any other interim periods or any future year or period.

WHO is kidding whom??

 

The Bottom Line: Even lipstick will NOT help this pig!!

  • I STILL question, "Whether HRGN formerly BSTG is a Ponzi Scheme?